Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

X Leleu

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
Leukemia|March 5, 2004
Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factorI Vande Broek, K Asosingh, V Allegaert, et al.
Medecine Et Maladies Infectieuses|December 19, 2019
Observational study of vaccination in cancer patients: How can vaccine coverage be improved?A Monier, M Puyade, M P Gallego Hernanz, et al.
Blood Cancer Journal|March 18, 2017
Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatmentX Leleu, C Kyriakou, I Vande Broek, et al.
Leukemia|February 16, 2011
Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myelomaP Moreau, F Cavallo, X Leleu, et al.
Leukemia|February 20, 1999
Isolated neurological relapse following stem cell transplantation in plasma cell leukemia: a report of two casesX Leleu, J P Jouet, I Plantier, et al.
British Journal of Haematology|May 31, 2001
Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphomaC Dumontet, F Morschhauser, P Solal-Celigny, et al.
Leukemia|December 4, 2010
Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemiaJ Rossignol, A-S Michallet, L Oberic, et al.
Leukemia|April 7, 2006
Autoimmune hemolytic anemias and IgG antierythrocyte autoantibodies in Waldenström's macroglobulinemia: association with FcgammaRIIa polymorphismS Poulain, I Dervite, X Leleu, et al.
La Revue De Medecine Interne|February 16, 2005
[Thalidomide: mechanisms of action and new insights in hematology]X Leleu, J B Micol, R Guieze, et al.
Annals of Hematology|May 27, 2020
R-CHOP appears to be the best first-line treatment for second primary diffuse large B cell lymphoma: a cancer registry studyT Systchenko, G Defossez, S Guidez, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
Leukemia|March 5, 2004
Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factorI Vande Broek, K Asosingh, V Allegaert, et al.
Medecine Et Maladies Infectieuses|December 19, 2019
Observational study of vaccination in cancer patients: How can vaccine coverage be improved?A Monier, M Puyade, M P Gallego Hernanz, et al.
Blood Cancer Journal|March 18, 2017
Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatmentX Leleu, C Kyriakou, I Vande Broek, et al.
Leukemia|February 16, 2011
Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myelomaP Moreau, F Cavallo, X Leleu, et al.
Leukemia|February 20, 1999
Isolated neurological relapse following stem cell transplantation in plasma cell leukemia: a report of two casesX Leleu, J P Jouet, I Plantier, et al.
British Journal of Haematology|May 31, 2001
Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphomaC Dumontet, F Morschhauser, P Solal-Celigny, et al.
Leukemia|December 4, 2010
Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemiaJ Rossignol, A-S Michallet, L Oberic, et al.
Leukemia|April 7, 2006
Autoimmune hemolytic anemias and IgG antierythrocyte autoantibodies in Waldenström's macroglobulinemia: association with FcgammaRIIa polymorphismS Poulain, I Dervite, X Leleu, et al.
La Revue De Medecine Interne|February 16, 2005
[Thalidomide: mechanisms of action and new insights in hematology]X Leleu, J B Micol, R Guieze, et al.
Annals of Hematology|May 27, 2020
R-CHOP appears to be the best first-line treatment for second primary diffuse large B cell lymphoma: a cancer registry studyT Systchenko, G Defossez, S Guidez, et al.
Pageof 6